Contact
Please use this form to send email to PR contact of this press release:
EMA recommends approval of adapted Nuvaxovid COVID-19 vaccine targeting Omicron XBB.1.5, CHMP, 31/10/2023
TO:
Please use this form to send email to PR contact of this press release:
EMA recommends approval of adapted Nuvaxovid COVID-19 vaccine targeting Omicron XBB.1.5, CHMP, 31/10/2023
TO: